Will the anti-Covid vaccine developed by Sanofi soon be usable within the European Union? The hypothesis is gaining momentum after the European Medicines Agency (EMA) announced on Tuesday, July 20 the launch of a procedure for“Continuous review” serum from the French pharmaceutical laboratory.
→ ANALYSIS. Covid vaccine: Sanofi wants to make up for lost time
If this stage is successful, Sanofi Pasteur may proceed with an authorization request for its Vidprevtyn vaccine.in the European Union (EU).
Encouraging preliminary results
But for this, the European agency must continue its procedure until it has sufficient information. “The EMA cannot foresee an overall timetable but the assessment of a possible request should take less time than usual due to the work carried out during the continuous review”, according to the agency.
The EMA’s decision to start the continuous review is based on preliminary results from laboratory studies and clinical studies in adults, the regulator explains. These results “Suggest that the vaccine triggers the production of antibodies that target Sars-CoV-2, the virus that causes Covid-19, and could help protect against the disease”, adds the EMA.
Four vaccines are currently authorized by the EMA in the EU: Pfizer-BioNTech, Moderna, AstraZeneca and Johnson & Johnson. The latter two are nevertheless used under certain age conditions in most European countries.